Herbal remedies: Adverse effects and drug interactions

American Family Physician

Volumn 59, Issue 5, 1999, Pages 1239-1244

  Cupp, Melanie Johns ^a  

^a WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPHEDRINE; GINKGO BILOBA EXTRACT; GINKOBA; HERBACEOUS AGENT; KAVA; UNCLASSIFIED DRUG;

ADVERSE DRUG REACTION; ARTICLE; DEPRESSION; DIET SUPPLEMENTATION; GINSENG; HERBAL MEDICINE; HUMAN; HYPERICUM PERFORATUM; SEDATION; SELF MEDICATION; WEIGHT REDUCTION;

DRUG INTERACTIONS; EPHEDRINE; GINKGO BILOBA; HERB-DRUG INTERACTIONS; HUMANS; KAVA; PANAX; PATIENT EDUCATION; PLANT EXTRACTS; PLANTS, MEDICINAL; TEACHING MATERIALS; THEALES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 0033104547     PISSN: 0002838X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Eisenberg DM, Kessler RC, Foster C, Norlock FE, Calkins DR, Delbanco TL. Unconventional medicine in the United States. Prevalence, costs, and patterns of use. N Engl J Med 1993;328:246-52.
2. Dietary Supplement Health and Education Act of 1994. Public Law No. 103-417, 1994.
3. Foster S. Herbal medicine: an introduction for pharmacists. NARD J 1996;10:127-44.
4. Rosenblatt M, Mindel J. Spontaneous hyphema associated with ingestion of Ginkgo biloba extract [Letter]. N Engl J Med 1997;336:1108.
5. Matthews MK Jr. Association of Ginkgo biloba with intracerebral hemorrhage [Letter]. Neurology 1998; 50:1933-4.
6. Rowin J, Lewis SL. Spontaneous bilateral subdural hematomas associated with chronic Ginkgo biloba ingestion. Neurology 1996;46:1775-6.
7. Gilbert GJ. Ginkgo biloba [Letter]. Neurology 1997; 48:1137.
8. Gianni LM, Dreitlein WB. Some popular OTC herbals can interact with anticoagulant therapy. US Pharmacist 1998;23(May):80,83-4,86.
9. St. John's wort. Med Lett Drugs Ther 1997;39:107-8.
10. Blumenthal M, ed. Complete German Commission E monographs.; therapeutic guide to herbal medicines. Austin, Tex.: American Botanical Council, 1998.
11. Cott JM. In vitro receptor binding and enzyme inhibition by Hypericum perforatum extract. Pharmacopsychiatry 1997;30(suppl 2): 108-12.
12. Gordon JB. SSRIs and St. John's wort: possible toxicity [Letter]? Am Fam Physician 1998;57:950, 953.
13. Müller WE, Rolli M, Schafer C, Hafner U. Effects of Hypericum extract (LI 160) in biochemical models of antidepressant activity. Pharmacopsychiatry 1997;30 (suppl 2):102-7.
14. Perovic S, Müller WE. Pharmacological profile of Hypericum extract. Effect on serotonin uptake by postsynaptic receptors. Arzneimittelforschung 1995; 45:1145-8.
15. Kerb R, Brockmoller J, Staffeldt B, Ploch M, Roots I. Single-dose and steady-state pharmacokinetics of hypericin and pseudohypericin. Antimicrob Agents Chemother 1996;40:2087-93.
16. Woelk H, Burkand G, Grunwald J. Benefits and risks of the Hypericum extract LI 160: drug monitoring study with 3250 patients. J Geriatr Psychiatry Neurol 1994;7(suppl 1):534-8.
17. Golsch S, Vocks E, Rakoski J, Brockow K, Ring J. Reversible increase in photosensitivity to UV-B caused by St. John's wort extract [German]. Hautarzt 1997;48:249-52.
18. Bove GM. Acute neuropathy after exposure to sun in a patient treated with St. John's wort [Letter]. Lancet 1998;352:1121-2.
19. The ephedras. Lawrence review of natural products. In: Drug facts and comparisons. St. Louis: Facts and Comparisons, 1995.
20. FDA warns against drug promotion of "herbal fenphen." In: FDA Talk Paper Rockville, Md.: Department of Health and Human Services, Food and Drug Administration, Nov. 6, 1997. Retrieved October 1998 from the World Wide Web: http://www. fda.gov/bbsAopics/ANSWERyANS00832.html.
21. Dietary supplements containing ephedrine alkaloids: proposed rule. 21 CFR Part 111 Fed Register 1997; 62(107):30677-724. Retrieved October 1998 from the Internet: http://frwebgate2.access.gpo.gov/cgi-bin.
22. Future marketing of ephedrine "street drugs" is "irresponsible," FDA tells six companies. Tan Sheet 1997;4(36):9. Retrieved October 1998 from the World Wide Web: http://www.dialogweb.com/ search/html.
23. Street drug alternatives with ephedra. FDA Consumer 1996;30(5):4.
24. Ephedrine alkaloids 8 mg per serving limit "too high," state food, drug officials say. Tan Sheet 1997, 5(50): 11-3. Retrieved October 1998 from the World Wide Web: http://www.dialogweb.com/search.html.
25. Serious "adverse" events reported for ephedrine supplements in 1-5 mg range - FDA. Tan Sheet 1997;4(36):4-6. Retrieved October 1998 from the World Wide Wed: http://www.dialogweb.com/ search.html.
26. Powell T, Hsu FF, Turk J, Hruska K. Ma-huang strikes again: ephedrine nephrolithiasis. Am J Kidney Dis 1998;32:153-9.
27. Tyler VE. The honest herbal. 3d ed. New York: Pharmaceutical Products Press, 1993.
28. Janetzky K, Morreale AP. Probable interaction between warfarin and ginseng. Am J Health/Syst Pharm 1997;54:692-3.
29. Schelosky L, Raffauf C, Jendroska K, Poewe W. Kava and dopamine antagonism [Letter]. J Neurol Neurosurg Psychiatry 1995;58:639-40.
30. Almedia JC, Grimsley EW. Coma from the health food store: interaction between kava and alprazolam [Letter]. Ann Intern Med 1996;125:940-1.
31. Jappe U, Franke I, Reinhold D, Gollnick HP. Sebotropic drug reaction resulting from kava-kava extract therapy: a new entity? J Am Acad Dermatol 1998;38: 104-6.